Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL
Blinatumomab 作为缓解后治疗方案,可替代巩固治疗和大部分维持化疗,并使新诊断的 B 系急性淋巴细胞白血病患儿的微小残留病灶(MRD)持续阴性。
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2023-008213
Mikhailova, Ekaterina; Popov, Alexander; Roumiantseva, Julia; Budanov, Oleg; Lagoyko, Svetlana; Zharikova, Liudmila; Miakova, Natalia; Litvinov, Dmitry; Khachatryan, Lili; Pshonkin, Alexey; Ponomareva, Natalia; Boichenko, Elmira; Varfolomeeva, Svetlana; Dinikina, Julia; Novichkova, Galina; Henze, Guenter; Karachunskiy, Alexander